BRSK2 and hepatocellular carcinoma: Chen et al confirmed our findings and proposed that low expression of FTCD is associated with poor prognosis and an aggressive tumor phenotype in HCC.[37] The sensitivity and specificity of FTCD expression levels in differentiating normal or liver cirrhosis from early well-differentiated HCCs are 90% and 86.7%, respectively.[38] Conversely, BRSK2, SPP1, and MMP1 expression levels were associated with a higher risk of poor prognosis in this study.